Se‐Hoon Lee

2004–2026 年に発表

別表記
Se-Hoon Lee
219
論文数
25,027
被引用数
86
h 指数
201
i10 指数

被引用数

Se‐Hoon Lee の年別被引用数2000 年: 被引用 3 件2004 年: 被引用 3 件2005 年: 被引用 13 件2006 年: 被引用 10 件2007 年: 被引用 12 件2008 年: 被引用 22 件2009 年: 被引用 24 件2010 年: 被引用 23 件2011 年: 被引用 53 件2012 年: 被引用 48 件2013 年: 被引用 105 件2014 年: 被引用 96 件2015 年: 被引用 136 件2016 年: 被引用 152 件2017 年: 被引用 203 件2018 年: 被引用 209 件2019 年: 被引用 697 件2020 年: 被引用 916 件2021 年: 被引用 1,115 件2022 年: 被引用 1,077 件2023 年: 被引用 952 件2024 年: 被引用 1,768 件2025 年: 被引用 1,243 件2026 年: 被引用 35 件2001〜2003 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,878 件、この内訳の 21.3%中国: 引用元論文 2,637 件、この内訳の 19.5%イタリア: 引用元論文 703 件、この内訳の 5.2%イギリス: 引用元論文 653 件、この内訳の 4.8%韓国: 引用元論文 613 件、この内訳の 4.5%日本: 引用元論文 605 件、この内訳の 4.5%フランス: 引用元論文 532 件、この内訳の 3.9%ドイツ: 引用元論文 523 件、この内訳の 3.9%スペイン: 引用元論文 421 件、この内訳の 3.1%カナダ: 引用元論文 372 件、この内訳の 2.8%オランダ: 引用元論文 311 件、この内訳の 2.3%スイス: 引用元論文 258 件、この内訳の 1.9%
0%21.3%その他 22.3%

分野

  • Medicine72.4%
  • Biochemistry, Genetics and Molecular Biology18.5%
  • Immunology and Microbiology5.4%
  • Computer Science1.1%
  • Environmental Science0.6%
  • Engineering0.5%
  • その他1.5%

トピック

  • Cancer Immunotherapy and Biomarkers11.7%
  • Lung Cancer Treatments and Mutations9%
  • Lung Cancer Research Studies5.2%
  • Cancer Genomics and Diagnostics4%
  • Lung Cancer Diagnosis and Treatment3.1%
  • Immunotherapy and Immune Responses2.8%
  • その他64.2%

共著者

全論文

検索で開く
  1. Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 1,030

  2. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

    著者: , , , , , , , , , , , , , , , , , , , , - Nature Communications 2020 被引用: 1,337

  3. Lung adenocarcinoma promotion by air pollutants

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marie-Julie Favé, Alastair Magness, Alejandro Suárez‐Bonnet, Simon L. Priestnall, Margreet Lüchtenborg, Katrina Lavelle, Joanna Pethick, Steven J. Hardy, Fiona E. McRonald, Meng‐Hung Lin, Clara I. Troccoli, Moumita Ghosh, York E. Miller, Daniel T. Merrick, Robert L. Keith, Maise Al Bakir, Chris Bailey, Mark S. Hill, Lao H. Saal, Yilun Chen, Anthony M. George, Christopher Abbosh, Nnennaya Kanu, Se‐Hoon Lee, Nicholas McGranahan, Christine D. Berg, Peter Sasieni, Richard S. Houlston, Clare Turnbull, Stephen Lam, Philip Awadalla, Eva Grönroos, Julian Downward, Tyler Jacks, Christopher Carlsten, Ilaria Malanchi, Allan Hackshaw, Kevin Litchfield, J.F. Lester, Amrita Bajaj, Apostolos Nakas, Azmina Sodha-Ramdeen, Keng Ang, Mohamad Tufail, Mohammed Fiyaz Chowdhry, Molly Scotland, Rebecca Boyles, Sridhar Rathinam, Claire Wilson, Domenic Marrone, Sean Dulloo, Dean A. Fennell, Gurdeep Matharu, Jacqui Shaw, Joan Riley, Lindsay Primrose, Ekaterini Boleti, Heather Cheyne, Mohammed S. Khalil, Shirley Richardson, Tracey Cruickshank, Gillian Price, Keith M. Kerr, Sarah Benafif, Kayleigh Gilbert, Babu Naidu, Akshay J. Patel, Aya Osman, Christer Lacson, Gerald Langman ほか 226 名 - Nature 2023 被引用: 790

  4. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cell 2021 被引用: 908

  5. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 1,176

  6. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 225

  7. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

    著者: , , , , , , , , , - Nature Communications 2019 被引用: 563

  8. Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniil Stroyakovskiy, Marina Peregudova, Mehmet Alı Nahıt Şendur, Ozan Yazıcı, Raffaele Califano, Vanesa Gutiérrez Calderón, Filippo de Marinis, Antonio Passaro, Sang‐We Kim, Shirish M. Gadgeel, John Xie, Tao Sun, Melissa Martínez, Mariah Ennis, E. Fennema, Mahesh Daksh, Dawn Millington, Isabelle Leconte, Ryota Iwasawa, Patricia Lorenzini, Mahadi Baig, Sujay Shah, Joshua Bauml, S. Martin Shreeve, Seema Sethi, R.E. Knoblauch, Hidetoshi Hayashi - New England Journal of Medicine 2024 被引用: 375

  9. Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Charles Lee, Kyoung Wan Yoon, Hansoo Park - Nature Microbiology 2021 被引用: 317

  10. Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 282

  11. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 被引用: 508

  12. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 164

  13. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2024 被引用: 153

  14. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

    著者: , , , , , , , , , , , , - Journal of Clinical Oncology 2017 被引用: 471

  15. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Laurent Greillier, Encarnação Teixeira, Danny Nguyen, Joshua K. Sabari, Angel Qin, Dariusz M. Kowalski, Mehmet Alı Nahıt Şendur, John Xie, Debopriya Ghosh, Ali Alhadab, Nahor Haddish‐Berhane, Pamela L. Clemens, Patricia Lorenzini, Remy B. Verheijen, Mohamed Gamil, Joshua Bauml, Mahadi Baig, Antonio Passaro, for the PALOMA-3 Investigators, Hiroaki Akamatsu, Mariam P. Alexander, Annalen Bleckmann, Federico Cappuzzo, Ying Cheng, Byoung Chul Cho, Timuçin Çil, Alexis B. Cortot, Pongwut Danchaivijitr, Till‐Oliver Emde, Dilek Erdem, Enriqueta Felip, F. Estevinho, Maria Lurdes Ferreira, Flavio Ferreira da Silva, Maria Campelo, Laurent Greillier, Alastair Greystoke, Ji‐Youn Han, Ping‐Chih Hsu, Jen‐Yu Hung, Mei Ji, Thomas John, Rohit Joshi, Young‐Chul Kim, Masashi Kondo, Ernesto Korbenfeld, Dariusz M. Kowalski, Se‐Hoon Lee, Natasha B. Leighl, Juan Li, Sheng-Hao Lin, Baogang Liu, Caigang Liu, John Seng-Hooi Low, Melina E. Marmarelis, Bartomeu Massutí, Anna R. Minchom, Sara Moore, Mor Moskovitz, Adnan Nagrial, Danny Nguyen, Silvia Novello, Y. Ohe, Mustafa Özgüroğlu, Özgür Özyılkan, Antonio Passaro, Nir Peled, Naiyarat Prasongsook, Angel Qin, Elisa F. Ramos ほか 22 名 - Journal of Clinical Oncology 2024 被引用: 114

  16. LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features

    著者: , , , , , , , , , - Nature Cancer 2024 被引用: 110

  17. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 被引用: 859

  18. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jie Bai, Paul Begin, Aleksandr Belonogov, Henri Berard, Radu Berceanu-Ion, Reyes Bernabe Caro, Igor Bondarenko, Reiner Bonnet, Joaquim Bosch Barrera, Carlos Brocca, Maciej Bryl, Alessandra Bulotta, Olivier Bylicki, Antonio Calles Blanco, Enric Carcereny, Leticia Carvalho, Cristina Cebotaru, Jamie Chaft, Veena Charu, Fabio Chaves, Jun Chen, Ke-Neng Chen, Haiquan Chen, Qixun Chen, Kevin Chen, Chi-Lu Chiang, Chao-Hua Chiu, Saulius Cicenas, Elena Ciubotaru, Tudor Ciuleanu, Ioana Ciurescu, Patrick Cobb, Corlia Coetzee, Dearbhaile Collins, Diego Cortinovis, Kimberly Costas, Dan Costin, Eduardo Henrique Cronemberger, Raymund Cuevo, Sinead Cuffe, Pedro Rafael Martins De Marchi, Tadeu de Paiva Junior, Angelo Delmonte, Ingel Demedts, Koenraad Deschepper, Josiane Dias, Christophe Dooms, Boris Duchemann, Carolina Dutra, Herbert Duvivier, Ekkehard Eigendorff, Vinicius Ernani, Martin Faehling, Luiza Faria, Alexander Fedenko, Hiran Fernando, Roberto Ferrara, Vittorio Ferrari, Gene Finley, Peter Fix, Marcos Flores, Samuel Fourie, Fabio Franke, Klaus-Peter Frohling, Muhammad Furqan, Cristian Gal, Robert Galamaga, Doina Ganea, Apar Kishor Ganti, Shugeng Gao ほか 176 名 - The Lancet 2024 被引用: 243

  19. The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

    著者: , , , , , , , , , , , , - Clinical Cancer Research 2019 被引用: 212

  20. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jim Looman, Christine K. Ratajczak, Shun Lü - Journal of Clinical Oncology 2024 被引用: 135

  21. Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

    著者: , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 359

  22. Synthetic lethality-mediated precision oncology via the tumor transcriptome

    著者: , , , , , , , , , , , , , , , , , , , , , , - Cell 2021 被引用: 162

  23. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

    著者: , , , , , , , , , , , , , , , , - The Lancet Respiratory Medicine 2019 被引用: 272

  24. Regulatory (FoxP3+) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer

    著者: , , , , , , , , , , - Scientific Reports 2020 被引用: 87